Philip Morris International (PMI) experienced a 5.6% jump in share prices after the FDA issued regulatory guidance favoring the commercialization of its products like ZYN Ultra and IQOS in the U.S. The company reported strong growth in its smoke-free segment, exceeding expectations in its first-quarter 2026 earnings, contributing to a 12.5% rise in shares since the start of the year. With a robust market cap of $291.3 billion and best-in-class margins, PMI is well-positioned in the evolving tobacco landscape under Altria's ownership.
“A United States court in 2006 · found that Philip Morris · disputed scientific findings linking smoking and disease knowing their assertions were false”